BAY 1125976
Alternative Names: BAY1125976Latest Information Update: 15 Apr 2019
Price :
$50 *
At a glance
- Originator Bayer
- Class Antineoplastics; Pyridines; Small molecules
- Mechanism of Action Proto-oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 15 Apr 2019 Discontinued - Phase-I for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, France, Switzerland, Germany, Switzerland, France, USA, Germany (PO) (Bayer pipeline, April 2019)
- 03 Apr 2019 Safety and efficacy data from a phase I trial in Solid tumours presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
- 28 Feb 2018 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (PO, Liquid)